2012
Multi-Modality Therapy for Cancer of the Esophagus and GE Junction
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.Peer-Reviewed Original ResearchConceptsGastroesophageal junctionNeoadjuvant platinum-based chemotherapyPostoperative adjuvant chemotherapyPlatinum-based chemotherapyIncidence of adenocarcinomaSubgroup of patientsHigh mortality rateAdjuvant chemotherapyOpinion statementCancersInduction chemotherapyNeoadjuvant treatmentPreoperative chemoradiationDistant recurrenceModality therapySystemic therapyDistal esophagusAdvanced tumorsPredictive biomarkersMortality rateTherapeutic outcomesChemotherapyEsophagusTherapyTherapy deliveryChemoradiation
2000
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D’Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. Journal Of Clinical Oncology 2000, 18: 904-14. PMID: 10673534, DOI: 10.1200/jco.2000.18.4.904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsArea Under CurveCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCetuximabCisplatinDose-Response Relationship, DrugDrug Administration ScheduleErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansInfusions, IntravenousLung NeoplasmsMaleNeoplasms, Glandular and EpithelialRecombinant Fusion ProteinsRemission InductionSafetyConceptsAntibody dosesMultiple doseSystemic clearancePhase I clinical trialWeeks of therapyDose-dependent pharmacokineticsCell lung cancerChimeric monoclonal antibodyCoadministration of cisplatinEpidermal growth factor receptorMurine chimeric monoclonal antibodyGrowth factor receptorDisease stabilizationPartial responseAdvanced tumorsSingle doseLung cancerClinical trialsDisease progressionEpithelial tumorsNonlinear pharmacokineticsPatientsDose levelsAntibody C225Relevant doses